

STUDY PROTOCOL

Open Access



An internet-based intervention for people with psychosis (EviBaS): study protocol for a randomized controlled trial

Nina Rüegg^{1*} , Steffen Moritz², Thomas Berger¹, Thies Lüdtkke^{2,3} and Stefan Westermann¹

Abstract

Background: Evidence shows that internet-based self-help interventions are effective in reducing symptoms for a wide range of mental disorders. To date, online interventions treating psychotic disorders have been scarce, even though psychosis is among the most burdensome disorders worldwide. Furthermore, the implementation of cognitive-behavioral therapy (CBT) for psychosis in routine health care is challenging. Internet-based interventions could narrow this treatment gap. Thus, a comprehensive CBT-based online self-help intervention for people with psychosis has been developed. The aim of this study is the evaluation of the feasibility and efficacy of the intervention compared with a waiting list control group.

Methods: The intervention includes modules on delusion, voice hearing, social competence, mindfulness, and seven other domains. Participants are guided through the program by a personal moderator. Usage can be amended by an optional smartphone app. In this randomized controlled trial, participants are allocated to a waiting list or an intervention of eight weeks. Change in positive psychotic symptoms of both groups will be compared (primary outcome) and predictors of treatment effects will be assessed.

Discussion: To our knowledge, this project is one of the first large-scale investigations of an internet-based intervention for people with psychosis. It may thus be a further step to broaden treatment options for people suffering from this disorder.

Trial registration: [NCT02974400](https://clinicaltrials.gov/ct2/show/study/NCT02974400) (clinicaltrials.gov), date of registration: November 28th 2016.

Keywords: Online intervention, CBT, Psychosis, Schizophrenia, Internet, Guided self-help

Background

Schizophrenia and other psychotic disorders are severe mental disorders with heterogeneous symptom profiles encompassing positive symptoms such as persecutory delusions and auditory verbal hallucinations as well as negative symptoms such as social isolation and avolition [1]. In addition, they are accompanied by neuropsychological impairments in attention, memory, and executive functioning [2–6]. Sleep is impaired in the majority of people experiencing persecutory delusions [7] and levels of worrying are high [8, 9]. Besides symptoms, stigmatization is a major source of distress in people diagnosed with schizophrenia [10], even in the context

of mental health care [11]. Lifetime prevalence of schizophrenia is about 1% and stable across different regions of the world and cultures [12]. Schizophrenia is accompanied by an enormous individual and societal burden [13, 14] and lies on position eight of the leading causes of disability-adjusted life years in 15- to 44-year-olds [15]. About 65% of individuals with a first episode relapse during the subsequent three years [16], resulting in inpatient costs about two to five times higher compared to non-relapsed patients [17].

As a complementary or alternative treatment option to antipsychotic medication [18], cognitive behavioral therapy for psychosis (CBTp) has emerged as an evidence-based treatment option for patients with schizophrenia and related disorders [19–24]. CBTp targets psychological mechanisms of symptom formation and maintenance that were primarily identified or corroborated using

* Correspondence: nina.ueegg@psy.unibe.ch

¹Department of Clinical Psychology and Psychotherapy, University of Bern, Fabrikstrasse 8, 3012 Bern, Switzerland

Full list of author information is available at the end of the article



experimental psychopathology research [25–27]. The therapeutic framework and techniques of CBTp are to a large extent similar to those of cognitive behavioral therapy (CBT) for depressive or anxiety disorders (cognitive restructuring, reality testing, etc.). For example, the distress (consequence) related to hearing voices (situation) is assumed to be determined not by hearing voices per se, but predominantly by automatic thoughts and the according belief system. Consequently, alternative helpful beliefs about voices established with the help of cognitive techniques are supposed to result in less distress [28]. CBTp is likely to be effective for patients who choose not to take antipsychotic medication, too [29]. In regular mental health care, the effectiveness of CBTp has also been asserted [30], and neurocognitive deficits, comorbidity and poorer functioning pose no barrier to improvement during CBTp [28]. Consequently, national regulations such as the United Kingdom National Institute for Health and Care Excellence (NICE) guideline recommend that CBTp should be offered to every person with psychotic symptoms [31].

Acceptance and Commitment Therapy (ACT) focuses on noticing rather than changing thoughts and feelings [32]. ACT seems to be effective in treating mental health problems [33]. In schizophrenia, ACT helps people to cope with psychotic experiences using strategies such as cognitive distancing, which is characterized by learning to see one's belief as a hypothetical statement rather than a fact. Instead of trying to change, modify, or control odd cognitions or disturbing sensory states, patients are encouraged to instead simply be aware of these experiences [34]. A meta-analysis showed a medium-sized effect of ACT on symptoms of psychosis [35].

The third type of treatment is the Metacognitive Training for psychosis (MCT), developed specifically for people with schizophrenia [36, 37]. MCT invites participants to critically evaluate cognitive biases such as jumping to conclusions and overconfidence in their thinking (metacognition). These biases might increase the likelihood of psychotic symptoms [38]. Studies show that MCT is efficacious in reducing psychotic symptoms [39, 40].

Despite the availability of evidence-based treatments for schizophrenia, 69% of patients remain untreated in countries with low and middle income [41]. In particular, the need for psychosocial treatments including CBTp remains unmet [42]. Even in highly developed countries such as the United Kingdom or Germany, the treatment gap for schizophrenia is large. In theory, the NICE guidelines proclaim that CBTp is mandatory for the treatment of psychosis [31]. In practice, more than 50% do not receive even a single session of CBTp [43]. In Germany, CBTp is virtually not represented in the mental health service [44]. To sum up, CBTp is effective, recommended, and has great potential to alleviate

psychological distress, but only a small fraction of patients with psychosis receives CBTp.

Internet-based cognitive behavioral therapy (iCBT) can help to overcome treatment gaps in many mental disorders [45]. In several psychological disorders, including anxiety and depression, internet-based treatments have proven to be efficacious and effective in randomized controlled trials (RCTs; for a comprehensive review, see [46]). Most of the growing body of evidence comes from studies evaluating guided internet-based self-help treatments. While patients work their way through a structured self-help program that is typically based on CBT manuals, therapists or coaches assist and support them via a secured e-mail system. Meta-analyses on internet-based treatments show a superiority of guided interventions in comparison to unguided, automated programs in terms of efficacy, adherence to treatment, and drop-out rates [47–49]. Main advantages of guided internet-based treatments include: (1) low-threshold accessibility, (2) flexible usage independent of time and place at a self-determined pace, (3) high levels of anonymity and privacy (which is an attractive feature for many persons with a mental disorder due to their fear of stigmatization) and (4) low costs of delivery to large populations [50].

People diagnosed with schizophrenia use the internet [51] and are able and willing to use mental health services on the internet, such as peer-to-peer support [52]. The feasibility of internet-based treatments for people with psychosis (iCBTp) is well documented for web-based interventions [53, 54] and also reported for smartphone interventions [55]. However, current internet-based programs differ in their comprehensiveness and focus. For instance, mixed results have been reported regarding the efficacy of internet-based psychoeducation programs [56], and the efficiency of internet-based programs targeting medication management [53, 57]. There is a pilot study on a more comprehensive web-based, CBTp-oriented program for auditory verbal hallucinations, but this program was delivered via computers in mental health care centres (and not online). The study provided promising results using an uncontrolled pre-post-design (Cohen's $d = 0.58$) [58]. None of the 21 participants with schizophrenia reported that the program was unhelpful and the authors report no adverse events, highlighting the feasibility of iCBTp in a computerized self-help format. A recent investigation of aforementioned program in an RCT design showed a comparable effect of the web-based intervention and usual care on levels of auditory hallucinations [59]. The study was able to show that patients with schizophrenia who used the web-based program, however, had increased significantly in social functioning and their knowledge about CBTp was larger than of those who did not use the program. In another study that investigated iCBT for people with schizophrenia, the web-based

program specifically targeted comorbid depressive symptoms. The intervention led to a significant decline in depression severity [60].

In summary, there is preliminary evidence that iCBTp for people diagnosed with schizophrenia could be beneficial. However, to the best of our knowledge, no larger trials on comprehensive treatments have been conducted. The overarching goal of this RCT is to evaluate a guided internet-based self-help intervention for people with psychosis. We developed a web-based program that is comprehensive in many respects: The program is not only based on CBT but also includes elements from its third wave, specifically ACT and MCT [34, 36]. Schizophrenia patients often have comorbidities, such as depression, which should be addressed in an appropriate treatment [61]. This program offers additional interventions for such comorbidities. Disrupted sleep and worrying, among other secondary symptoms, are crucial in the formation and maintenance of psychotic disorders [25]. These factors are considered in the intervention as well. According to a review, the effects of smartphone-enhanced self-help are promising [62]. The intervention therefore includes an accompanying smartphone app for access in symptom-relevant situations in daily life. The app is expected to facilitate a transfer of skills to real world settings. Finally, a specific goal of the intervention was not to overstate negative consequences of the disorder [63] and solely focus on deficits, but to specifically target resources of the participants [64].

Treatment adherence in schizophrenia has been a well discussed topic predominantly in medication treatment

[65]. But also in psychological treatments, rather high dropout rates are reported (e.g. prematurely terminated treatments by 45% of patients) [66]. This led us to look for factors that might influence treatment adherence. Among others, suggested mediators are treatment motivation [67] and working alliance with the therapist [68]. Overall, the study tests whether a comprehensive internet-based self-help program with an accompanying smartphone app reduces symptomatology in people with schizophrenia.

Methods

Study design

The study is an RCT of parallel design comparing the efficacy of guided internet-based self-help treatment for patients with schizophrenia to a waiting list control group (Fig. 1). Participants in the control group receive access to treatment after the intervention period of eight weeks. The long-term effect of the intervention is measured by a follow-up assessment six months after the intervention period has ended and is not part of the RCT design.

Sample size

A power analysis with the software G*Power [69] resulted in a target sample size of 128 to detect a medium-sized effect ($f = 0.25$) with $\alpha = 0.05$ and a power of 0.80 for an ANCOVA. Including an assumed attrition rate of about 10%, the final number of participants should reach 140.




Fig. 1 Participant flow

Recruitment

Participants will be recruited in three different ways: First, the study staff will contact former patients with diagnoses of schizophrenia who consented to get contacted and inquire whether they are interested in participating in this study via e-mail. Second, study information will be sent out to psychiatric institutions in Switzerland and Germany. The health staff at those institutions can then distribute the information to interested and suitable patients directly, for example those patients who leave the institution and look for a continuation treatment. Lastly, online bulletin boards and informative websites on psychoeducation specifically created for people affected by schizophrenia will be targeted for publishing descriptions and links to the study.

Eligibility criteria

To be included, participants must fulfill all inclusion criteria and not show any exclusion criteria described below. Suffering from other psychiatric disorders such as depression or anxiety disorders (part of the former 'axis I' disorders) does not lead to exclusion as long as the schizophrenia spectrum disorder is the primary diagnosis.

Inclusion criteria are:

- 1 An age of 18 years or older.
- 2 Provision of electronic informed consent.
- 3 Access to the internet.
- 4 Command of the German language.
- 5 Fulfilling the diagnostic criteria for either schizophrenia, delusional disorder or schizoaffective disorder in their lifetime according to the structured Mini International Neuropsychiatric Interview (MINI) [70] administered during a telephone

interview. These diagnoses are allowed to be partly remitted.

- 6 A score of three or higher on the items assessing delusions (P1), hallucinations (P3) or suspiciousness/persecution (P6) on the Positive and Negative Syndrome Scale (PANSS) [71] showing that some positive symptoms remain.
- 7 Simultaneous treatment with antipsychotic medication (or regular psychological or psychiatric care in Germany).

Exclusion criteria are:

- 1 Acute suicidality.
- 2 Representing an acute danger for others.
- 3 No agreement on compiling an emergency plan.
- 4 Diagnosis of an acute neurological disease of the central nervous system that needs to be treated.

Randomization

Participants eligible for inclusion will be randomly allocated to one of the two groups (intervention or waiting list control group). Randomization and allocation will be prepared in advance by an independent researcher. This researcher will remain blinded to all processes within the intervention. An automated, web-based randomization service (www.random.org) [72] will be used to generate the randomization list. The allocation ratio will be 1:1.

Intervention

The intervention called *EviBaS* (for *Evidence-Based Self-help* intervention) consists of an online program based on CBT principles, while also including components of ACT and MCT treatments. A smartphone app provides the possibility of exercising the modules in everyday life.

Table 1 Modules of the online program EviBaS

Name	Description
Introduction	Reflect on thoughts, feelings and behavior to understand and decrease the symptom burden.
Feelings of Threat	Review the effects of paranoia on individual goals and needs.
Voice Hearing	Learn strategies to reduce distress caused by hearing voices (better coping, influence the evaluation of voices).
Self-Worth	Find forgotten strengths and train a balanced sense of self.
Overcoming Depression	Set up activities and scrutinize depressing thoughts.
Worrying	Minimize upholding factors of worry and tackle worries with problem solving skills.
Sleep	Discuss maintaining factors of the sleep disorder, such as sleep hindering thoughts or disadvantageous surrounding factors.
Mindfulness	Exercise to direct your attention on one thing without judgement.
Metacognition	Learn in interactive exercises to avoid jumping to conclusions and overconfidence in errors.
Social Competence	Plan and train three different types of social situations: enforcing interests, shaping relationships, and winning sympathies.
Relapse Prevention	Collect individual warning signs and plan ahead.

There are 11 text-based modules in the online program, addressing a variety of topics (see Table 1). Each module includes texts and a worksheet. The worksheets can also be accessed via the optional app. The only mandatory module is the introductory one. After completion, the participants can choose from the remaining ten modules freely. Relapse prevention is recommended as the last module. Study participants are asked to work on approximately one to two modules per week. The time required to finish one module may vary, but will usually not exceed 60 min. The intervention is self-paced, so that participants are able to work on topics they prioritize, such as emotional issues rather than positive symptomatology [73].

While working with the program, participants will be in contact with a personal moderator if they want to. The moderator will guide the participants through the program with at least one message per week. The main goal of this steady contact is to help participants structure their usage of the program and to encourage regular participation [47]. If necessary (in case of a participant not using the intervention for seven days), the moderator reminds the participant to interact with the program. Participants' questions are answered within three workdays by moderators. There is a biweekly supervision of all the moderators in the study team led by a licenced psychotherapist with extensive experience in CBTp.

Measures

The primary outcome is the reduction of psychotic symptoms (positive symptoms such as voice hearing and paranoid delusions) at post assessment (directly after the completion of the intervention). Secondary outcomes include the level of symptomatology at follow-up, the number of dropouts and the results of all secondary questionnaires which evaluate quality of life, depression severity, treatment satisfaction, the influence of treatment expectancy, and process measures, among others (see Table 2). Assessments will be completed at baseline, eight weeks and 32 weeks. For an overview of all primary and secondary outcome measures, predictors and moderators, as well as process measures, see Table 2.

Primary outcome measures

Positive and Negative Syndrome Scale (PANSS)

The PANSS [71] was the first standardized evaluation tool for symptoms of schizophrenia [74]. It assesses 30 symptoms, which can be grouped into five factors: positive symptoms, negative symptoms, disorganization, excitement, and emotional distress [1]. The positive symptom factor serves as the primary outcome of this study. It includes nine items (delusions, hallucinations, unusual thought content, suspiciousness, grandiosity, somatic concern, active social avoidance, lack of judgment and insight,

and (less) difficulty in abstraction). In this study, clinicians administer the PANSS via telephone.

MINI International Neuropsychiatric Interview (MINI)

The MINI is a diagnostic structured interview for the assessment of psychiatric diagnoses [70], with a corresponding German version [75]. The specificity of the MINI was reported as good for all diagnoses (ranging from 0.72 to 0.97) [70]. In this study, a part of the MINI (depressive episode, suicidality, manic episode, and psychosis) was also administered via telephone.

Paranoia Checklist

The Paranoia Checklist was developed by Freeman et al. in 2005 [76] and assesses the frequency, degree of conviction, and associated distress of a wide range of paranoid thoughts. The three subscales each include the same 18 items, which are rated on a five-point Likert scale: The first subscale measures the frequency of paranoid thoughts (ranging from 'does not apply at all' to 'applies very well'; adapted), the second subscale measures the degree of conviction (from 'not at all convinced' to 'absolutely convinced') and the third subscale surveys the level of distress (from 'not distressing' to 'very distressing'). Cronbach's alpha, as an estimate of reliability, is reported as .90 or above, which stands for an excellent internal consistency of the Paranoia Checklist [76].

Launay-Slade Hallucination Scale (LSHS-R)

The LSHS-R is the revised version of the LSHS, developed by Launay and Slade in 1981 [77]. It includes 12 items and measures the predisposition to hallucinations on a wide spectrum [78]. There is a German version of the LSHS-R, which shows a Cronbach's alpha of .87 in a patient sample and therefore is comparable to the original [79]. The five-point Likert scale ranges from 0 ('certainly does not apply to me') to 4 ('certainly applies to me') and there is a sum score that will be compared between both groups of participants.

Secondary outcome measures

Delusion and Voices Self-Assessment (DV-SA)

The DV-SA has two subscales, a Delusions Scale (DS) and a Voices Scale (VS). The former contains five items to assess patients' opinions about the dominant delusional idea and the latter includes ten items about the subjective dimensions of auditory hallucinations [80]. All responses of the participants are rated on two four-point Likert scales, from 0 (absence of problems) to 3 (the severest of problems), with the highest achievable total score of 15 for the DS and 33 for the VS [80]. For

Table 2 An internet-based intervention for people with psychosis (EviBaS): Schedule of enrolment, intervention and assessments

Timepoint	Study period				
	Enrolment t-1	Allocation t0	Post-allocation		Close-out
			t1 intervention/ waiting period	t2 post assessment	t3 follow-up assessment
Eligibility screen	X				
Informed consent	X				
Allocation		X			
Interventions:					
EviBaS intervention group			X		
Waiting list control group			X		
Assessments:					
Primary outcome measures					
Positive and Negative Syndrome Scale (PANSS)	X			X	X
Mini International Neuropsychiatric Interview (MINI)	X			X	X
Paranoia Checklist	X			X	X
Launay-Slade Hallucination Scale (LSHS-R)	X			X	X
Secondary outcome measures					
Delusion and Voices Self-Assessment (DV-SA)	X			X	X
Rosenberg Self-Esteem Scale (RSES)	X			X	X
Insomnia Severity Index (ISI)	X			X	X
Penn State Worry Questionnaire - Abbreviated (PSWQ-A)	X			X	X
Patient Health Questionnaire (PHQ-9)	X			X	X
Box Task	X			X	X
Mindful Attention Awareness Scale (MAAS)	X			X	X
Interpersonal Competence Questionnaire (ICQ; subscales initiation and negative assertion)	X			X	X
Incongruence questionnaire (K-INK)	X			X	X
World Health Organization Quality of Life Assessment (WHO-QoL-BREF)	X			X	X
Internalized Stigma of Mental Illness – short version (ISMI)	X			X	X
Predictors and moderators					
Medication Adherence Rating Scale (MARS-D)	X			X	X
Attitudes towards Psychological Online Interventions (APOI)	X				
Credibility/Expectancy Questionnaire (CEQ)	X				
University of Rhode Island Change Assessment (URICA)	X				
Client Satisfaction Questionnaire (CSQ)				X	
Questionnaire Side Effects Psychosis and Internet (QueSPI)				X	
Process measures					
Working Alliance Inventory – Short Revised (WAI-SR)		X			
Intermediate Assessments Questionnaire		X			

this study, we changed the time period referenced in the DV-SA from 1 month to 1 week.

Incongruence questionnaire (K-INK)

The K-INK [81] is a short version of a questionnaire (INK) that measures the degree of realization of motivational goals in the participant's life. Those goals

can be classified into two groups: approach goals and avoidance goals. On a five-point Likert scale, the K-INK measures approach incongruence, avoidance incongruence, and total incongruence. Internal consistency (as measured by Cronbach's alpha) for the K-INK is reported as ranging between .52 and .87 [81].

World Health Organization Quality of Life Assessment (WHO-QoL-BREF)

The WHO-QoL-BREF consists of 26 items and is a standard questionnaire to measure the quality of life [82]. Cronbach's alpha values range from .66 to .84, indicating an acceptable internal consistency [82]. The WHO-QoL-BREF demonstrates good discriminant validity [82]. In this study, it is administered both in baseline and post assessments and the participants have to indicate their level of agreement on a five-point rating scale with changing answer formats.

Rosenberg Self-Esteem Scale (RSES)

The RSES measures self-esteem on a four-point Likert scale. The RSES shows a high reliability and validity for global self-worth [83]. It demonstrates an excellent internal consistency (Guttman scale coefficient of reproducibility of .92) [84]. Moreover, the two week test-retest reliability revealed high correlations of .85 and .88, indicating excellent stability [84]. Higher scores on the RSES indicate higher self-esteem.

Insomnia Severity Index (ISI)

The ISI is a brief measure for insomnia and is composed of seven items. Each of these items is rated on a five-point Likert scale, ranging from 0 ('not at all') to 4 ('extremely'). Studies reported adequate psychometric properties for ISI versions in English and French [85, 86].

Penn State Worry Questionnaire - Abbreviated (PSWQ-A)

The PSWQ [87] is a questionnaire designed to assess the tendency to worry. In this study, an abbreviated eight-item version (PSWQ-A) was used [88]. The measure is scored on a five-point Likert scale from 1 ('not at all typical') to 5 ('very typical'). The PSWQ-A items have good internal consistency highlighted by reported Cronbach's alpha ranging from .87 to .89 and .94 [88, 89]. Scores for the PSWQ-A range from 8 to 40 [90].

Patient Health Questionnaire (PHQ-9)

The PHQ-9 measures depression severity [91]. It scores all nine DSM-IV criteria for depression on a rating scale from 0 ('not at all') to 3 ('nearly every day'). A score of 20 represents severe depression. Internal consistency of the PHQ-9 is excellent with a Cronbach's alpha of between 0.86 and 0.89 [91]. In this study, the short German version (PHQ-D) was used [92] and the item on suicidality also serves as an indication of the necessity of exclusion from the study.

Box Task

In the Box Task [93], participants are confronted with grey boxes on the computer screen, concealing two distinct colours. Participants have to gather information

about which of the two colours is more frequent by clicking on said boxes. When they decide that they have gathered sufficient information, they can choose the more frequent colour. This experimental paradigm has been administered in a previous study [94]. If the amount of information an individual gathers before making a decision is low this indicates a tendency to jump to conclusions [27]. Jumping to conclusions has been found to be associated with schizophrenia and delusions [95].

Mindful Attention Awareness Scale (MAAS)

The MAAS is a questionnaire measuring mindfulness on a six-point Likert scale. Cronbach's alpha of the MAAS has been reported as .81 [96].

Interpersonal Competence Questionnaire (ICQ)

The ICQ is originally a 40-item questionnaire for the assessment of five domains of interpersonal competence [97]. In this study, only two of the five domains are surveyed: initiation of relationships and negative assertion. Moreover, a recently published short version of the ICQ (called ICQ-15) [98] was used to pick out the six items of the two subscales (three for each domain). The internal consistency of the total scale was high (Cronbach's alpha = .87) and the reliability coefficients of the subscales were the highest two coefficients of the five subscales: .73 (for initiation of relationships) and .75 (for negative assertion) [98]. The German version of this questionnaire has been validated as well [99].

Internalized Stigma of Mental Illness (ISMI) – Short version

The ISMI is a questionnaire measuring the internalized stigma of participants [100]. In this study, the short version of the ISMI was used, which includes 10 items with four-point Likert scales [101]. To evaluate the results, one calculates the mean of those items. A mean score between 1.00 and 2.50 points stands for no internalized stigma, while a mean score between 2.51 and 4.00 stands for high internalized stigma. The German version of the ISMI showed a high internal consistency (Cronbach's alpha = .92), which was calculated in a study with 139 participants [102].

Predictors and moderators

Medication Adherence Rating Scale (MARS-D)

The MARS [103] consists of five items rated on a five-point Likert scale. These items measure a participant's non-adherent behavior from 1 ('always') to 5 ('never'). A higher score indicates higher adherence to the prescribed medication. MARS-D is the German adaptation of this questionnaire developed by Mahler et al. [104]. Internal consistency of the MARS-D

(Cronbach's alpha ranging from .60 to .69) was reported as satisfactory and comparable to the original [104].

Attitudes towards Psychological Online Interventions (APOI)

The APOI measures patients' attitudes towards an online intervention [105]. It reveals certain prejudgments of a study participant, which might influence the outcome parameters and the motivation. Sixteen items are displayed and the level of agreement with each item can be indicated on a five-point rating scale (ranging from 'no agreement' to 'total agreement'). A factor analysis of the APOI showed four dimensions: (a) scepticism and perception of risks (b) confidence in effectiveness (c) technologization threat and (d) anonymity benefits. The APOI shows acceptable to good internal consistency and a good content validity is assumed, because the construction of items was done deductively as well as inductively [105].

Credibility/Expectancy Questionnaire (CEQ)

The CEQ is an economic scale to measure treatment expectancy and rationale credibility [106]. The dimensions measured by the CEQ can possibly moderate the outcome. In this study, participants rate items according to two dimensions - one dimension is related to thinking and one is related to feeling. On four of six items, the rating scale ranges from 'no agreement' to the treatment rationale to 'total agreement' on a nine-point rating scale. For the remaining two items, participants can indicate the subjective symptom improvement from 0% to 100% in steps of 10%. The CEQ demonstrated a high internal consistency of between .84 and .85 [106].

University of Rhode Island Change Assessment (URICA)

The URICA [107] is a measure of readiness to change. The 32-item URICA consists of four subscales (eight items each) that correspond to four stages of change (precontemplation, contemplation, action and maintenance) [108]. Internal consistency for the total URICA was reported as excellent (Cronbach's alpha = .83) [109]. This study used a short version of the German URICA (URICA-S) [110], where items are rated on a five-point Likert scale ranging from 1 ('not applicable at all') to 5 ('very applicable').

Client Satisfaction Questionnaire (CSQ)

The CSQ asks participants to what extent they were satisfied with the intervention [111]. The internal consistency of the CSQ was .93, which stands for an excellent score. There is evidence for a strong construct validity of the CSQ as well [111]. Because it measures treatment satisfaction, it can only be administered at post assessment. Due to its shortness and comprehensiveness, the CSQ is very suitable for mailed surveys [112] and can therefore also be

administered in an online format. The German version (called ZUF-8) [113] is being used in this current study. The eight items can be answered on a four-point rating scale [113].

Questionnaire about Side Effects Psychosis and Internet (QueSPI)

This questionnaire assesses the negative effects of internet-based interventions for psychotic patients. It was developed within the research group as part of a pilot study leading up to the current project [114]. Detailed information can be found in the Additional file 1.

Process measures

Working Alliance Inventory – Short Revised (WAI-SR)

As a measure of the weekly variation of the therapeutic alliance, the WAI-SR [114] was included in the study in its German version [115]. It goes back to the Working Alliance Inventory (WAI) [116] and differentiates between goal, task and bond alliance dimensions. Each of those dimensions is represented by four items. The WAI-SR uses a five-point rating scale representing the frequency of positive alliance experiences (ranging from 'rarely' to 'always'). Cronbach's alpha of the subscale scores ranges from .85 to .90, and of the total scores from .91 to .92, indicating excellent internal consistency [114].

Intermediate Assessments Questionnaire

The study group designed a questionnaire to briefly measure symptoms and mental states that were expected to change over the course of the online intervention. Each therapeutic topic covered in the online intervention is represented by a single item in the intermediate assessments questionnaire, such as auditory hallucinations, quality of sleep, self-worth, worry, or depression. Additionally, potentially psychosis-related thinking styles (e.g. jumping to conclusions) are assessed via single items. Five out of 14 items were newly created by the authors, the remaining 9 items were adopted from German versions of established questionnaires (e.g. PHQ-9) [117], or taken and translated from experience sampling studies on schizophrenia (e.g. 'I feel suspicious') [118]. The intermediate assessments questionnaire uses a five-point rating scale ranging from 'not at all true' to 'absolutely true' and can be read in the Additional file 2.

Data collection and management

At baseline, participants complete an online assessment including several questionnaires described above. An electronic informed consent and demographic questions will be displayed at the beginning of this online survey. Participants must also indicate their e-mail address and telephone number, which are processed independently from other data. The process of baseline assessment lasts approximately 35

to 40 min. After completion and if no inclusion criteria is not met, a telephone interview with the participant will be arranged. This telephone interview includes two diagnostic interviews (MINI and PANSS, also described above) and the development of an individual emergency plan in case of acute suicidality or psychotic relapse with each participant. The interview lasts approximately 45 to 60 min. If the participant scores below the cutoff on all of the PANSS items (delusions, hallucinations or suspiciousness/persecution), or if the participant reports neither current nor past psychotic symptoms, he or she is excluded from participation and receives a short self-help manual as a compensation for the assessment participation. When inclusion criteria are met, the participants are randomized to one of two groups. The participant either gets access to the online intervention program immediately or after a waiting period of eight weeks. After completion of the intervention period, post assessment and a second telephone interview are administered. The same procedure takes place during the follow-up assessment six months after the intervention period.

Statistical analyses

Based on the intention to treat sample, a linear mixed-model repeated measures ANOVA with time (T1-T2) as a within-group factor and study condition as a between-group factor will be used for the main research question. Mixed-model repeated measures ANOVA uses all available data of each subject and does not require the substitution of missing values. Sensitivity analysis will be conducted to analyze the impact of dropout on the results. The significance level is set at 5%. We are also interested in possible mediators and/or moderators of the relation between the internet-based self-help intervention and positive psychotic symptoms. We will therefore test whether predictors identified in the literature, such as treatment motivation, working alliance or usage of the intervention could mediate and/or moderate the main effect [119]. To evaluate these possible predictors of treatment outcome, we use change scores of outcome measures as the dependent variables.

Ethical aspects and data safety

The *Cantonal Ethics Committee Bern* (ID: 03/14) as well as the *German Society for Psychology* (ID: SM052015_CH) have approved of this study. Data safety is ensured by several means: The program and app usage are independent of any personal data. Conversely, the communication via the secured e-mail system contains no information that would allow the identification of a participant in EviBaS. Sensitive data (where personal information such as the e-mail address can be linked to login data for the online program) is stored exclusively non-electronically in a locked closet at one study site. Diagnostic staff will not know the

identification of the participants in the program and will be blinded for the allocation of participants in the two groups, whereas moderating staff will not know the contact information of the participants. Breach of blinding will be reported. Network security is achieved through SSL encryption. All staff members who are in contact with study participants, are required to fill out a non-disclosure agreement.

Discussion

EviBaS has been developed as one of the first fully encompassing iCBT programs for people with psychosis. People with schizophrenia spectrum disorders suffer from a heavy burden of symptoms and stigmatization [13]. Psychological evidence-based treatments for schizophrenia exist, but only a small portion of affected people receive them [120]. Bridging the treatment gap in the psychological care for people with severe mental disorders is therefore of utmost importance. This project wants to reach people who do not receive psychological treatment but are looking for support. Internet-based interventions might even be able to reach a group of patients that discontinued a previous face-to-face therapy [121]. Given the efficacy of CBTp on hallucinations and delusions [122], as well as of iCBT in other mental disorders [46], the EviBaS self-help program is expected to reduce symptomatology. Negative effects and long-lasting effects of the treatment will be assessed. This study will also add to our understanding of how people with schizophrenia use internet-based interventions.

Additional files

Additional file 1: Questionnaire about Side Effects Psychosis and Internet (QueSPI). (DOCX 20 kb)

Additional file 2: Intermediate Assessments Questionnaire. (DOCX 12 kb)

Abbreviations

ACT: Acceptance and Commitment Therapy; APOI: Attitudes towards Psychological Online Interventions Questionnaire; CBT: Cognitive-behavioral therapy; CBTp: Cognitive behavioral therapy for psychosis; CEQ: Credibility/Expectancy Questionnaire; CSQ: Client Satisfaction Questionnaire; DV-SA: Delusion and Voices Self-Assessment; EviBaS: Evidence-based self-help intervention; iCBT: Internet-based cognitive behavioral therapy; iCBTp: Internet-based treatments for people with psychosis; ICQ: Interpersonal Competence Questionnaire; ISI: Insomnia Severity Index; ISMI: Internalized Stigma of Mental Illness Questionnaire; K-INK: Incongruence Questionnaire (short version); LSHS-R: Launay-Slade Hallucination Scale; MAAS: Mindful Attention Awareness Scale; MARS-D: Medication Adherence Rating Scale; MCT: Metacognitive Training; MINI: Mini International Neuropsychiatric Interview; PANSS: Positive and Negative Syndrome Scale; PHQ-9: Patient Health Questionnaire with 9 Items; PSWQ-A: Penn State Worry Questionnaire - Abbreviated; QueSPI: Questionnaire about Side Effects Psychosis and Internet; RCT: Randomized controlled trial; RSES: Rosenberg Self-Esteem Scale; URICA: University of Rhode Island Change Assessment; WAI-SR: Working Alliance Inventory - Short Revised; WHO-QoL-BREF: World Health Organization Quality of Life Assessment

Acknowledgements

We would like to acknowledge Pascal Zaugg for his contribution in developing the EviBaS-App as well as Julia Bierbrodt, Birgit Hottenrott, Lena

Jelinek, Helena Meyer, Johanna Schröder and Ruth Veckenstedt for their contribution in writing the self-help modules.

Funding

This study was funded by the Swiss National Science Foundation (project number 159384) and the German Research Foundation (project number DFG Mo 969/17–1). The funding body played no role in the design of the study, the collection of data or in writing the manuscript.

Availability of data and materials

Not applicable.

Trial status

Trial start date: December 6th 2016.

Currently recruiting ($N_{\text{current}} = 66$ as of 30th October 2017)

Authors' contributions

NR wrote the first draft of the manuscript. SW, SM, TB and NR designed the study. All authors contributed to and approved the final manuscript.

Ethics approval and consent to participate

The Cantonal Ethics Committee Bern (ID: 03/14) as well as the German Society for Psychology (ID: SM052015_CH) have approved of this study. Informed consent to participate in the study is being obtained from every participant.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Department of Clinical Psychology and Psychotherapy, University of Bern, Fabrikstrasse 8, 3012 Bern, Switzerland. ²Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. ³Department of Psychology, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway.

Received: 31 October 2017 Accepted: 28 February 2018

Published online: 13 April 2018

References

- van der Gaag M, Hoffman T, Remijsen M, Hijman R, de Haan L, van Meijel B, et al. The five-factor model of the positive and negative syndrome scale II: a ten-fold cross-validation of a revised model. *Schizophr Res*. 2006;85:280–7.
- Forbes NF, Carrick LA, McIntosh AM, Lawrie SM. Working memory in schizophrenia: a meta-analysis. *Psychol Med*. 2009;39(6):889–905.
- Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. *Neuropsychology*. 1998;12(3):426.
- Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. *Neuropsychology*. 2009;23(3):315–36.
- Schaefer J, Giangrande E, Weinberger DR, Dickinson D. The global cognitive impairment in schizophrenia: consistent over decades and around the world. *Schizophr Res*. 2013;150(1):42–50.
- Fatouros-Bergman H, Cervenka S, Flyckt L, Edman G, Farde L. Meta-analysis of cognitive performance in drug-naïve patients with schizophrenia. *Schizophr Res*. 2014;158(1):156–62.
- Freeman D, Pugh K, Vorontsova N, Southgate L. Insomnia and paranoia. *Schizophr Res*. 2009;108(1):280–4.
- Freeman D, Garety PA. Worry, worry processes and dimensions of delusions: an exploratory investigation of a role for anxiety processes in the maintenance of delusional distress. *Behav Cogn Psychother*. 1999;27(1):47–62.
- Freeman D, Garety P. Advances in understanding and treating persecutory delusions: a review. *Soc Psychiatry Psychiatr Epidemiol*. 2014;49(8):1179–89.
- Gerlinger G, Hauser M, Hert M, Lacluyse K, Wampers M, Correll CU. Personal stigma in schizophrenia spectrum disorders: a systematic review of prevalence rates, correlates, impact and interventions. *World Psychiatry*. 2013;12(2):155–64.
- Mestdagh A, Hansen B. Stigma in patients with schizophrenia receiving community mental health care: a review of qualitative studies. *Soc Psychiatry Psychiatr Epidemiol*. 2014;49(1):79–87.
- Jablensky A. Schizophrenia: recent epidemiologic issues. *Epidemiol Rev*. 1995;17(1):10–20.
- Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. *Schizophr Bull*. 2004;30(2):279–93.
- Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010. *Lancet*. 2013;382(9904):1575–86.
- World Health Organization. International classification of functioning, disability and health (ICF). Geneva: World Health Organization; 2001.
- Caseiro O, Pérez-Iglesias R, Mata I, Martínez-García O, Pelayo-Terán JM, Tabares-Seisdedos R, et al. Predicting relapse after a first episode of non-affective psychosis: a three-year follow-up study. *J Psychiatr Res*. 2012;46(8):1099–105.
- Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. *BMC Psychiatry*. 2010;10(1):2.
- Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. *Mol Psychiatry*. 2009;14(4):429.
- Jauhar S, McKenna PJ, Radua J, Fung E, Salvador R, Laws KR. Cognitive-behavioural therapy for the symptoms of schizophrenia: systematic review and meta-analysis with examination of potential bias. *Br J Psychiatry*. 2014;204(1):20–9.
- Mehl S, Werner D, Lincoln TM. Does cognitive behavior therapy for psychosis (CBTp) show a sustainable effect on delusions? A meta-analysis. *Front Psychol*. 2015;6:1450.
- Pfammatter M, Junghan UM, Brenner HD. Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses. *Schizophr Bull*. 2006;32(1):64–80.
- Pontillo M, de Crescenzo F, Vicari S, Pucciari ML, Averna R, Santonastaso O, et al. Cognitive behavioural therapy for auditory hallucinations in schizophrenia: a review. *World J Psychiatry*. 2016;6(3):372–80.
- Turner DT, van der Gaag M, Karyotaki E, Cuijpers P. Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. *Am J Psychiatry*. 2014;171(5):523–38.
- Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. *Schizophr Bull*. 2008;34(3):523–37.
- Freeman D. Persecutory delusions: a cognitive perspective on understanding and treatment. *The Lancet Psychiatry*. 2016;3(7):685–92.
- Freeman D, Garety PA, Kuipers E, Fowler D, Bebbington PE. A cognitive model of persecutory delusions. *Br J Clin Psychol*. 2002;41(4):331–47.
- Garety PA, Freeman D. The past and future of delusions research: from the inexplicable to the treatable. *Br J Psychiatry*. 2013;203(5):327–33.
- Lincoln TM. Kognitive Verhaltenstherapie der Schizophrenie: Ein individuenzentrierter Ansatz. Göttingen: Hogrefe Verlag; 2014.
- Morrison AP, Turkington D, Pyle M, Spencer H, Brabban A, Dunn G, et al. Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: a single-blind randomised controlled trial. *Lancet*. 2014;383(9926):1395–403.
- Lincoln TM, Ziegler M, Mehl S, Kesting ML, Lüllmann E, Westermann S, et al. Moving from efficacy to effectiveness in cognitive behavioral therapy for psychosis: a randomized clinical practice trial. *J Consult Clin Psychol*. 2012;80(4):674.
- National Institute for Clinical Excellence. Psychosis and schizophrenia in adults: treatment and management. London: The National Institute for Health and Care Excellence; 2014.
- Tai S, Turkington D. The evolution of cognitive behavior therapy for schizophrenia: current practice and recent developments. *Schizophr Bull*. 2009;35(5):865–73.
- A-Tjak JG, Davis ML, Morina N, Powers MB, Smits JA, Emmelkamp PM. A meta-analysis of the efficacy of acceptance and commitment therapy for clinically relevant mental and physical health problems. *Psychother Psychosom*. 2015;84(1):30–6.

34. Pankey J, Hayes SC. Acceptance and commitment therapy for psychosis. *Int J Psychol Psychol Ther.* 2003;3(2):311–28.
35. Khoury B, Lecomte T, Gaudiano BA, Paquin K. Mindfulness interventions for psychosis: a meta-analysis. *Schizophr Res.* 2013;150(1):176–84.
36. Aghotor J, Pfueller U, Moritz S, Weisbrod M, Roesch-Ely D. Metacognitive training for patients with schizophrenia (MCT): feasibility and preliminary evidence for its efficacy. *J Behav Ther Exp Psychiatry.* 2010;41(3):207–11.
37. Moritz S, Woodward TS. Metacognitive training in schizophrenia: from basic research to knowledge translation and intervention. *Curr Opin Psychiatry.* 2007;20(6):619–25.
38. Broome MR, Johns LC, Valli I, Woolley JB, Tabraham P, Brett C, et al. Delusion formation and reasoning biases in those at clinical high risk for psychosis. *Br J Psychiatry.* 2007;191(5):38–42.
39. Eichner C, Berna F. Acceptance and efficacy of Metacognitive training (MCT) on positive symptoms and delusions in patients with schizophrenia: a meta-analysis taking into account important moderators. *Schizophr Bull.* 2016;42(2):952–62.
40. Moritz S, Vitzthum F, Randjbar S, Veckenstedt R, Woodward TS. Metakognitives Training für schizophrene Patienten (MKT). Manual; 2010.
41. Lora A, Kohn R, Levav I, McBain R, Morris J, Saxena S. Service availability and utilization and treatment gap for schizophrenic disorders: a survey in 50 low- and middle-income countries. *Bull World Health Organ.* 2012;90(1):47–54.
42. Mojtabai R, Fochtmann L, Chang SW, Kotov R, Craig TJ, Bromet E. Unmet need for mental health care in schizophrenia: an overview of literature and new data from a first-admission study. *Schizophr Bull.* 2009;35(4):679–95.
43. Shafran R, Clark DM, Fairburn CG, Arntz A, Barlow DH, Ehlers A, et al. Mind the gap: improving the dissemination of CBT. *Behav Res Ther.* 2009;47(11):902–9.
44. Klingberg S, Wittorf A. Evidenzbasierte Psychotherapie bei schizophrenen Psychosen. *Nervenarzt.* 2012;83(7):907–18.
45. Andersson G. Using the internet to provide cognitive behaviour therapy. *Behav Res Ther.* 2009;47(3):175–80.
46. Andersson G. Internet-delivered psychological treatments. *Annu Rev Clin Psychol.* 2016;12:157–79.
47. Baumeister H, Reichler L, Munzinger M, Lin J. The impact of guidance on internet-based mental health interventions – a systematic review. *Internet Interv.* 2014;1:205–15.
48. Richards D, Richardson T. Computer-based psychological treatments for depression: a systematic review and meta-analysis. *Clin Psychol Rev.* 2012;32(4):329–42.
49. Spek V, Cuijpers P, Nyklicek I, Riper H, Keyzer J, Pop V. Internet-based cognitive behaviour therapy for symptoms of depression and anxiety: a meta-analysis. *Psychol Med.* 2007;37(3):319–28.
50. Titov N, Dear BF, Ali S, Zou JB, Lorian CN, Johnston L, et al. Clinical and cost-effectiveness of therapist-guided internet-delivered cognitive behavior therapy for older adults with symptoms of depression: a randomized controlled trial. *Behav Ther.* 2015;46(2):193–205.
51. Schrank B, Sibitz I, Unger A, Ameringer M. How patients with schizophrenia use the internet: qualitative study. *J Med Internet Res.* 2010;12(5):e70.
52. Naslund JA, Aschbrenner KA, Marsch LA, Bartels SJ. The future of mental health care: peer-to-peer support and social media. *Epidemiol Psychiatr Sci.* 2016;25(2):113–22.
53. Alvarez-Jimenez M, Alcazar-Corcoles MA, Gonzalez-Blanch C, Bendall S, McGorry PD, Gleeson JF. Online, social media and mobile technologies for psychosis treatment: a systematic review on novel user-led interventions. *Schizophr Res.* 2014;156(1):96–106.
54. Anttila M, Välimäki M, Hätönen H, Luukkaala T, Kaila M. Use of web-based patient education sessions on psychiatric wards. *Int J Med Inform.* 2012;81(6):424–33.
55. Ben-Zeev D, Brenner CJ, Begale M, Duffecy J, Mohr DC, Mueser KT. Feasibility, acceptability, and preliminary efficacy of a smartphone intervention for schizophrenia. *Schizophr Bull.* 2014;40(6):1244–53.
56. van der Krieke L, Wunderink L, Emerencia AC, de Jonge P, Sysma S. E-mental health self-management for psychotic disorders: state of the art and future perspectives. *Psychiatr Serv.* 2014;65(1):33–49.
57. Välimäki M, Kannisto KA, Vahlberg T, Hätönen H, Adams CE. Short text messages to encourage adherence to medication and follow-up for people with psychosis (mobile.net): randomized controlled trial in Finland. *J Med Internet Res.* 2017;19(7):e245.
58. Gottlieb JD, Romeo KH, Penn DL, Mueser KT, Chiko BP. Web-based cognitive-behavioral therapy for auditory hallucinations in persons with psychosis: a pilot study. *Schizophr Res.* 2013;145(1):82–7.
59. Gottlieb JD, Gidugu V, Maru M, Tepper MC, Davis MJ, Greenwald J, et al. Randomized controlled trial of an internet cognitive behavioral skills-based program for auditory hallucinations in persons with psychosis. *Psychiatr Rehabil J.* 2017;40(3):283–92.
60. Moritz S, Schröder J, Klein JP, Lincoln TM, Andreou C, Fischer A, et al. Effects of online intervention for depression on mood and positive symptoms in schizophrenia. *Schizophr Res.* 2016;175(1):216–22.
61. Mcmillan KA, Enns MW, Cox BJ, Sareen J. Comorbidity of axis I and II mental disorders with schizophrenia and psychotic disorders: findings from the National Epidemiologic Survey on alcohol and related conditions. *Can J Psychiatr.* 2009;54(7):477–86.
62. Donker T, Petrie K, Proudfoot J, Clarke J, Birch MR, Christensen H. Smartphones for smarter delivery of mental health programs: a systematic review. *J Med Internet Res.* 2013;15(11):e247. <https://doi.org/10.2196/jmir.2791>.
63. Moritz S, Mahlke CI, Westermann S, Ruppelt F, Lysaker PH, Bock T, et al. Embracing psychosis: a cognitive insight intervention improves personal narratives and meaning-making in patients with schizophrenia. *Schizophr Bull.* 2018;44(2):307–16. <https://doi.org/10.1093/schbul/sbx072>.
64. Flückiger C, Caspar F, grosse Holtforth M, Willutzki U. Working with patients' strengths: a microprocess approach. *Psychother Res.* 2009;19(2):213–23.
65. Morken G, Widen JH, Grawe RW. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. *BMC Psychiatry.* 2008;8(1):32.
66. Startup M, Jackson MC, Bendix S. North Wales randomized controlled trial of cognitive behaviour therapy for acute schizophrenia spectrum disorders: outcomes at 6 and 12 months. *Psychol Med.* 2004;34(3):413–22.
67. Alfnsson S, Olsson E, Hursti T. Motivation and treatment credibility predicts dropout, treatment adherence, and clinical outcomes in an internet-based cognitive behavioral relaxation program: a randomized controlled trial. *J Med Internet Res.* 2016;18(3):e52.
68. Haug T, Nordgreen T, Öst L, Tangen T, Kvale G, Hovland OJ, et al. Working alliance and competence as predictors of outcome in cognitive behavioral therapy for social anxiety and panic disorder in adults. *Behav Res Ther.* 2016;77:40–51.
69. Faul F, Erdfelder E, Lang A, Buchner A. G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods.* 2007;39(2):175–91.
70. Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Sheehan KH, et al. The mini international neuropsychiatric interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI. *Eur Psychiatry.* 1997;12(5):224–31.
71. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull.* 1987;13(2):261–76.
72. Haahr M. [Random.org](http://www.random.org): True Random Number Service. www.random.org; 1998. Accessed 26 Sept 2016.
73. Moritz S, Berna F, Jaeger S, Westermann S, Nagel M. The customer is always right? Subjective target symptoms and treatment preferences in patients with psychosis. *Eur Arch Psychiatry Clin Neurosci.* 2017;267(4):335–9. <https://doi.org/10.1007/s00406-016-0694-5>.
74. Lançon C, Auquier P, Nayt G, Reine G. Stability of the five-factor structure of the positive and negative syndrome scale (PANSS). *Schizophr Res.* 2000;42(3):231–9.
75. Ackenheil M, Stotz-Ingenlath G, Dietz-Bauer R, Vossen A. MINI Mini International Neuropsychiatric Interview, German Version. Munich; 1999.
76. Freeman D, Garety PA, Bebbington PE, Smith B, Rollinson R, Fowler D, et al. Psychological investigation of the structure of paranoia in a non-clinical population. *Br J Psychiatry.* 2005;186(5):427–35.
77. Launay G, Slade P. The measurement of hallucinatory predisposition in male and female prisoners. *Pers Individ Dif.* 1981;2(3):221–34.
78. Waters FAV, Badcock JC, Maybery MT. Revision of the factor structure of the Launay-Slade hallucination scale (LSHS-R). *Pers Individ Dif.* 2003;35(6):1351–7.
79. Lincoln TM, Keller E, Rief W. Die Erfassung von Wahn und Halluzinationen in der Normalbevölkerung. *Diagnostica.* 2009;55(1):29–40. doi: <https://doi.org/10.1026/0012-1924.55.1.29>.
80. Pinto A, Gigantesco A, Morosini P, La Pia S. Development, reliability and validity of a self-administered questionnaire on subjective opinion about delusions and voices. *Psychopathology.* 2007;40(5):312–20.
81. grosse Holtforth M, Grawe K. Der Inkongruenzfragebogen (INK). *Z Klin Psychol Psychother.* 2003;32(4):315–23.
82. Harper A. Development of the World Health Organization WHOQOL-BREF quality of life assessment. *Psychol Med.* 1998;28(3):551–8.

83. Gray-Little B, Williams VS, Hancock TD. An item response theory analysis of the Rosenberg self-esteem scale. *Personal Soc Psychol Bull.* 1997;23(5):443–51.
84. Rosenberg M. Rosenberg Self-Esteem Scale (RSE). In: *Conceiving the self.* New York: Basic Books; 1979:61–2.
85. Bastien CH, Vallières A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. *Sleep Med.* 2001; 2(4):297–307.
86. Blais FC, Gendron L, Mimeault V, Morin CM. Evaluation de l'insomnie: Validation de trois questionnaires. *L'Encéphale Rev Psychiatr Clin Biol Thérapeutique.* 1997;23:447–53.
87. Meyer TJ, Miller ML, Metzger RL, Borkovec TD. Development and validation of the Penn State worry questionnaire. *Behav Res Ther.* 1990;28(6):487–95.
88. Hopko DR, Stanley MA, Reas DL, Wetherell JL, Beck JG, Novy DM, et al. Assessing worry in older adults: confirmatory factor analysis of the Penn State worry questionnaire and psychometric properties of an abbreviated model. *Psychol Assess.* 2003;15(2):173–83.
89. Crittendon J, Hopko DR. Assessing worry in older and younger adults: psychometric properties of an abbreviated Penn State worry questionnaire (PSWQ-A). *J Anxiety Disord.* 2006;20(8):1036–54.
90. Wutrich VM, Johnco C, Knight A. Comparison of the Penn State worry questionnaire (PSWQ) and abbreviated version (PSWQ-A) in a clinical and non-clinical population of older adults. *J Anxiety Disord.* 2014;28(7):657–63.
91. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med.* 2001;16:606–13.
92. Löwe B, Spitzer RL, Zipfel S, Herzog W. Gesundheitsfragebogen für Patienten (PHQ D). Kompletteversion und Kurzform. Testmappe mit Manual, Fragebögen, Schablonen. Karlsruhe: Pfizer; 2002.
93. Clark L, Robbins TW, Ersche KD, Sahakian BJ. Reflection impulsivity in current and former substance users. *Biol Psychiatry.* 2006;60(5):515–22.
94. Balzan RP, Ephraums R, Delfabbro P, Andreou C. Beads task vs. box task: the specificity of the jumping to conclusions bias. *J Behav Ther Exp Psychiatry.* 2017;56:42–50.
95. Dudley R, Taylor P, Wickham S, Hutton P. Psychosis, delusions and the 'jumping to conclusions' reasoning bias: a systematic review and meta-analysis. *Schizophr Bull.* 2015;42(3):652–65.
96. Brown KW, Ryan RM. The benefits of being present: mindfulness and its role in psychological well-being. *J Pers Soc Psychol.* 2003;84(4):822–48.
97. Buhrmester D, Furman W, Wittenberg MT, Reis HT. Five domains of interpersonal competence in peer relationships. *J Pers Soc Psychol.* 1988; 55(6):991–1008.
98. Coroiu A, Meyer A, Gomez-Garibello CA, Brähler E, Hessel A, Körner A. Brief form of the interpersonal competence questionnaire (ICQ-15): development and preliminary validation with a German population sample. *Eur J Psychol Assess.* 2015;31(4):272–9.
99. Kanning UP. Development and validation of a German-language version of the interpersonal competence questionnaire (ICQ). *Eur J Psychol Assess.* 2006;22(1):43–51.
100. Ritsher JB, Otilingam PG, Grajales M. Internalized stigma of mental illness: psychometric properties of a new measure. *Psychiatry Res.* 2003;121(1):31–49.
101. Boyd JE, Otilingam PG, DeForge BR. Brief version of the internalized stigma of mental illness (ISMI) scale: psychometric properties and relationship to depression, self esteem, recovery orientation, empowerment, and perceived devaluation and discrimination. *Psychiatr Rehabil J.* 2014;37(1):17–23.
102. Sibitz I, Friedrich ME, Unger A, Bachmann A, Benesch T, Amering M. Internalisiertes Stigma bei Schizophrenie: Validierung der deutschen Version der Internalized Stigma of Mental Illness-Skala (ISMI). *Psychiatr Prax.* 2013; 40(2):83–91.
103. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. *J Psychosom Res.* 1999;47(6):555–67.
104. Mahler C, Hermann K, Horne R, Ludt S, Haefeli WE, Szecsenyi J, et al. Assessing reported adherence to pharmacological treatment recommendations. Translation and evaluation of the medication adherence report scale (MARS) in Germany. *J Eval Clin Pract.* 2010;16(3):574–9.
105. Schröder J, Sautier L, Kriston L, Berger T, Meyer B, Spaeth C, et al. Development of a questionnaire measuring attitudes towards psychological online interventions - the APOL. *J Affect Disord.* 2015;187:136–41.
106. Devilly GJ, Borkovec TD. Psychometric properties of the credibility/ expectancy questionnaire. *J Behav Ther Exp Psychiatry.* 2000;31(2):73–86.
107. McConaughy EA, DiClemente CC, Prochaska JO, Velicer WF. Stages of change in psychotherapy: a follow-up report. *Psychother Theory, Res, Pract, Train.* 1989;26(4):494–503.
108. Amodi N, Lamb RJ. Convergent and concurrent validity of the contemplation ladder and URICA scales. *Drug Alcohol Depend.* 2004;73(3):301–6.
109. Dozois DJA, Westra HA, Collins KA, Fung TS, Garry JKF. Stages of change in anxiety: psychometric properties of the University of Rhode Island change assessment (URICA) scale. *Behav Res Ther.* 2004;42(6):711–29.
110. Mander J, Wittorf A, Teufel M, Schlarb A, Hautzinger M, Zipfel S, et al. Patients with depression, somatoform disorders, and eating disorders on the stages of change: validation of a short version of the URICA. *Psychotherapy.* 2012;49(4):519–27.
111. Attkisson CC, Zwick R. The client satisfaction questionnaire: psychometric properties and correlations with service utilization and psychotherapy outcome. *Eval Program Plann.* 1982;5(3):233–7.
112. De Wilde EF, Hendriks VM. The client satisfaction questionnaire: psychometric properties in a Dutch addict population. *Eur Addict Res.* 2005; 11(4):157–62.
113. Schmidt J, Wittmann WW. Fragebogen zur Messung der Patientenzufriedenheit. In: *Diagnostische Verfahren in der Psychotherapie.* Göttingen: Hogrefe; 2002. p. 392–6.
114. Hatcher RL, Gillaspay JA. Development and validation of a revised short version of the working alliance inventory. *Psychother Res.* 2006;16(1):12–25.
115. Wilmers F, Munder T, Leonhart R, Herzog T, Plasmann R, Barth J, et al. Die deutschsprachige Version des Working Alliance Inventory – short revised (WAI-SR) – Ein schulübergreifendes, ökonomisches und empirisch validiertes Instrument zur Erfassung der therapeutischen Allianz. *Klin. Diagnostik und Eval.* 2008;1(3):343–58.
116. Horvath AO, Greenberg LS. Development and validation of the working alliance inventory. *J Couns Psychol.* 1989;36(2):223–33.
117. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. *JAMA.* 1999;282(18): 1737–44.
118. Kramer I, Simons CJ, Wigman JTW, Collip D, Jacobs N, Derom C, et al. Time-lagged moment-to-moment interplay between negative affect and paranoia: new insights in the affective pathway to psychosis. *Schizophr Bull.* 2013;40(2):278–86.
119. Fairchild AJ, Mackinnon DP. A general model for testing mediation and moderation effects. *Prev Sci.* 2009;10(2):87–99.
120. Bechdolf A, Klingberg S. Psychotherapy of schizophrenia: not a problem of evidence, but a problem of implementation. *Psychiatr Prax.* 2014;41(1):8–10.
121. Andersson G, Titov N. Advantages and limitations of internet-based interventions for common mental disorders. *World Psychiatry.* 2014;13(1):4–11.
122. van der Gaag M, Valmaggia LR, Smit F. The effects of individually tailored formulation-based cognitive behavioural therapy in auditory hallucinations and delusions: a meta-analysis. *Schizophr Res.* 2014;156(1):30–7.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

